DK3274364T3 - Modificeret botulinumneurotoksin - Google Patents
Modificeret botulinumneurotoksin Download PDFInfo
- Publication number
- DK3274364T3 DK3274364T3 DK16714713.1T DK16714713T DK3274364T3 DK 3274364 T3 DK3274364 T3 DK 3274364T3 DK 16714713 T DK16714713 T DK 16714713T DK 3274364 T3 DK3274364 T3 DK 3274364T3
- Authority
- DK
- Denmark
- Prior art keywords
- botulinum neurotoxin
- modified botulinum
- modified
- neurotoxin
- botulinum
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 title 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/952—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562138818P | 2015-03-26 | 2015-03-26 | |
| PCT/US2016/024211 WO2016154534A1 (en) | 2015-03-26 | 2016-03-25 | Engineered botulinum neurotoxin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3274364T3 true DK3274364T3 (da) | 2021-10-18 |
Family
ID=55661643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16714713.1T DK3274364T3 (da) | 2015-03-26 | 2016-03-25 | Modificeret botulinumneurotoksin |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11268080B2 (da) |
| EP (2) | EP3274364B1 (da) |
| CN (2) | CN115925835A (da) |
| DK (1) | DK3274364T3 (da) |
| ES (1) | ES2895853T3 (da) |
| HK (1) | HK1248737A1 (da) |
| HU (1) | HUE057258T2 (da) |
| PL (1) | PL3274364T3 (da) |
| PT (1) | PT3274364T (da) |
| RU (1) | RU2746736C2 (da) |
| TW (1) | TWI725963B (da) |
| WO (1) | WO2016154534A1 (da) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2847241T3 (es) | 2012-05-30 | 2021-08-02 | Harvard College | Neurotoxina botulínica genéticamente modificada |
| WO2016154534A1 (en) * | 2015-03-26 | 2016-09-29 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
| GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| CA3030155A1 (en) * | 2016-07-08 | 2018-01-11 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| US11117935B2 (en) | 2016-08-24 | 2021-09-14 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
| JP7227901B2 (ja) * | 2016-10-20 | 2023-02-22 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | ボツリヌス神経毒素の活性を測定するためのインビトロアッセイ法及び細胞ベースのアッセイ法 |
| WO2018236873A1 (en) | 2017-06-19 | 2018-12-27 | President And Fellows Of Harvard College | Methods and compositions for treating a microbial infection |
| TWI810228B (zh) * | 2017-12-20 | 2023-08-01 | 英商艾普森生物製藥有限公司 | 自主神經系統障礙之治療 |
| SE542539C2 (en) * | 2018-02-26 | 2020-06-02 | Toxotech Ab | Chimeric botulinum neurotoxin heavy chain binding domain |
| WO2019227222A1 (en) * | 2018-05-30 | 2019-12-05 | The Governing Council Of The University Of Toronto | Methods and kits for identifying a protein associated with receptor-ligand interactions |
| GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
| GB202001353D0 (en) | 2020-01-31 | 2020-03-18 | Ipsen Biopharm Ltd | Treatment of skin conditions |
| GB202003813D0 (en) | 2020-03-16 | 2020-04-29 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| EP4121100A2 (en) | 2020-03-16 | 2023-01-25 | Ipsen Biopharm Limited | Modified botulinum neurotoxin for treating limb spasticity |
| GB202011055D0 (en) | 2020-07-17 | 2020-09-02 | Ipsen Bioinnovation Ltd | Treatment of post-operative pain |
| GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
| CN114958887B (zh) * | 2021-02-26 | 2024-10-25 | 重庆誉颜制药有限公司 | 一种经修饰的毒素多肽的制备方法 |
| AU2022247196A1 (en) | 2021-03-30 | 2023-10-05 | Ipsen Biopharm Limited | Treatment of pain & inflammatory disorders |
| US20250066755A1 (en) | 2021-03-30 | 2025-02-27 | Ipsen Biopharm Limited | Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders |
| JP2024534384A (ja) | 2021-09-16 | 2024-09-20 | イプセン バイオファーム リミテッド | 頸部ジストニアを治療する用途の修飾ＢｏＮＴ／Ａ |
| KR20240067100A (ko) | 2021-09-23 | 2024-05-16 | 입센 바이오팜 리미티드 | 대상체의 안검 근육에 이환된 장애의 치료에 사용하기 위한 변형된 bont/a |
| GB202113602D0 (en) | 2021-09-23 | 2021-11-10 | Ipsen Biopharm Ltd | Treatment of a disorder affecting an eyelid muscle of a subject |
| GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
| CA3234608A1 (en) | 2021-11-22 | 2023-05-25 | Ipsen Biopharm Limited | Treatment of pain |
| GB202206361D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of a facial dystonia |
| GB202206362D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| GB202206353D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of cervical dystonia |
| GB202206348D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
| GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
| GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
| GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
| WO2025093845A1 (en) | 2023-11-01 | 2025-05-08 | Ipsen Biopharm Limited | Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines |
| WO2025093844A1 (en) | 2023-11-01 | 2025-05-08 | Ipsen Biopharm Limited | Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm |
| GB202318884D0 (en) | 2023-12-11 | 2024-01-24 | Ipsen Biopharm Ltd | Formulation |
| GB202320108D0 (en) | 2023-12-28 | 2024-02-14 | Ipsen Biopharm Ltd | Biosensor |
| GB202404021D0 (en) | 2024-03-20 | 2024-05-01 | Ipsen Biopharm Ltd | Cell-based neurotoxin assay |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US5053005A (en) | 1989-04-21 | 1991-10-01 | Gary E. Borodic | Chemomodulation of curvature of the juvenile spine |
| US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| PT758900E (pt) | 1994-05-09 | 2002-09-30 | William J Binder | Toxina botulinica para a reducao da dor de cabeca devida a enxaqueca |
| US6203794B1 (en) | 1994-05-31 | 2001-03-20 | Allergan Sales, Inc. | Modification of clostridial toxins for use as transport proteins |
| GB9411138D0 (en) | 1994-06-03 | 1994-07-27 | Microbiological Res Authority | Toxin assay |
| US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US5721215A (en) | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| EP1105153A4 (en) | 1996-08-28 | 2005-01-19 | Ophidian Pharm Inc | POLYVALENT VACCINE AGAINST NEUROTOXIN (CLOSTRIDIUM BOTILINUM) |
| GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US20040033241A1 (en) | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
| NZ537120A (en) * | 2002-05-31 | 2008-07-31 | Univ Jefferson | Compositions and methods for transepithelial molecular transport |
| US7148041B2 (en) | 2003-09-25 | 2006-12-12 | Allergan, Inc. | Animal product free media and processes for obtaining a botulinum toxin |
| ES2374822T3 (es) | 2004-02-24 | 2012-02-22 | Allergan, Inc. | Ensayo de selección de toxinas botul�?nicas. |
| KR100668570B1 (ko) | 2004-06-28 | 2007-01-16 | 입센 리미티드 | 복재신경 포착에 의한 무릎 관절 통증 치료를 위한,보툴리눔 독소를 포함하는 제약 조성물 |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| US8128940B2 (en) * | 2005-03-15 | 2012-03-06 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| US7985554B2 (en) | 2005-10-14 | 2011-07-26 | Wisconsin Alumni Research Foundation | Botulinum neurotoxin A receptor and the use thereof |
| DE102005051789B4 (de) | 2005-10-28 | 2014-08-07 | Toxogen Gmbh | Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen |
| FR2902341B1 (fr) | 2006-06-16 | 2011-02-25 | Scras | Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace |
| FR2907680B1 (fr) | 2006-10-27 | 2012-12-28 | Scras | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux |
| FR2910327B1 (fr) | 2006-12-22 | 2013-04-26 | Scras | Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida. |
| WO2009015840A2 (en) | 2007-07-27 | 2009-02-05 | Merz Pharma Gmbh & Co. Kgaa | Polypeptide for targeting of neural cells |
| US8586081B2 (en) | 2007-09-20 | 2013-11-19 | University Of Massachusetts | Detoxified recombinant botulinum neurotoxin |
| WO2009042165A2 (en) * | 2007-09-25 | 2009-04-02 | Thomas Jefferson University | Mutant botulinum neurotoxin serotype a polypeptide and uses thereof |
| FR2930447B1 (fr) | 2008-04-25 | 2010-07-30 | Sod Conseils Rech Applic | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique |
| CN102131823A (zh) | 2008-08-29 | 2011-07-20 | 德国麦氏大药厂 | 具有改变的持久性的梭状芽孢杆菌神经毒素 |
| TW201023928A (en) | 2008-11-12 | 2010-07-01 | Kythera Biopharmaceuticals Inc | Systems and methods for delivery of biologically active agents |
| EP2419128B1 (en) | 2009-04-14 | 2018-06-06 | Medical College of Wisconsin, Inc. | Engineered botulinum neurotoxin |
| US8440204B2 (en) | 2009-04-30 | 2013-05-14 | Wisconsin Alumni Research Foundation | Subtype of Closteridium botulinum neurotoxin type A and uses thereof |
| NZ604322A (en) | 2010-05-20 | 2015-01-30 | Allergan Inc | Degradable clostridial toxins |
| ES2847241T3 (es) * | 2012-05-30 | 2021-08-02 | Harvard College | Neurotoxina botulínica genéticamente modificada |
| GB201219602D0 (en) * | 2012-10-31 | 2012-12-12 | Syntaxin Ltd | Recombinant clostridium botulinum neurotoxins |
| US9216210B2 (en) * | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
| WO2016154534A1 (en) * | 2015-03-26 | 2016-09-29 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| MX2018015254A (es) * | 2016-06-08 | 2019-08-16 | Childrens Medical Center | Neurotoxinas botulinicas modificadas. |
| US11117935B2 (en) * | 2016-08-24 | 2021-09-14 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
-
2016
- 2016-03-25 WO PCT/US2016/024211 patent/WO2016154534A1/en not_active Ceased
- 2016-03-25 PL PL16714713T patent/PL3274364T3/pl unknown
- 2016-03-25 US US15/561,355 patent/US11268080B2/en active Active
- 2016-03-25 RU RU2017134357A patent/RU2746736C2/ru active
- 2016-03-25 ES ES16714713T patent/ES2895853T3/es active Active
- 2016-03-25 CN CN202210985546.1A patent/CN115925835A/zh active Pending
- 2016-03-25 TW TW105109524A patent/TWI725963B/zh active
- 2016-03-25 DK DK16714713.1T patent/DK3274364T3/da active
- 2016-03-25 HU HUE16714713A patent/HUE057258T2/hu unknown
- 2016-03-25 EP EP16714713.1A patent/EP3274364B1/en active Active
- 2016-03-25 CN CN201680025744.6A patent/CN107548402B/zh active Active
- 2016-03-25 EP EP21189503.2A patent/EP3981783A1/en active Pending
- 2016-03-25 PT PT167147131T patent/PT3274364T/pt unknown
- 2016-03-25 HK HK18108651.3A patent/HK1248737A1/zh unknown
-
2022
- 2022-01-24 US US17/582,958 patent/US20220154160A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3274364B1 (en) | 2021-08-04 |
| US20220154160A1 (en) | 2022-05-19 |
| RU2017134357A3 (da) | 2020-03-25 |
| TW201639877A (zh) | 2016-11-16 |
| US11268080B2 (en) | 2022-03-08 |
| EP3981783A1 (en) | 2022-04-13 |
| WO2016154534A1 (en) | 2016-09-29 |
| TWI725963B (zh) | 2021-05-01 |
| PL3274364T3 (pl) | 2022-01-10 |
| RU2017134357A (ru) | 2019-04-05 |
| PT3274364T (pt) | 2021-11-05 |
| CN107548402B (zh) | 2022-08-19 |
| HK1248737A1 (zh) | 2018-10-19 |
| EP3274364A1 (en) | 2018-01-31 |
| US20180080016A1 (en) | 2018-03-22 |
| ES2895853T3 (es) | 2022-02-22 |
| CN115925835A (zh) | 2023-04-07 |
| RU2746736C2 (ru) | 2021-04-20 |
| CN107548402A (zh) | 2018-01-05 |
| HK1249119A1 (zh) | 2018-10-26 |
| HUE057258T2 (hu) | 2022-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3274364T3 (da) | Modificeret botulinumneurotoksin | |
| FIC20240028I1 (fi) | Retifanlimabi | |
| FIC20240014I1 (fi) | Elranatamabi | |
| IL263754A (en) | A novel botulinum neurotoxin and its derivatives | |
| DK3452071T3 (da) | Kimære neurotoksiner | |
| LT3347061T (lt) | Įšvirkščiami makroporiniai hidrogeliai | |
| HUE046451T2 (hu) | Hegesztõeszköz | |
| DK3283625T3 (da) | Nukleasemedieret genomeditering | |
| EP3362556C0 (en) | POLYPEPTIDE VARIANTS | |
| LT3256580T (lt) | Cisteino proteazė | |
| PT3137621T (pt) | Fabrico de neurotoxinas de clostridium botulinum recombinantes | |
| DK3242884T3 (da) | Kationiske neurotoksiner | |
| DK3331528T3 (da) | Muskarinagonister | |
| DK3386954T3 (da) | Dimere kontrastmidler | |
| EP3290364A4 (en) | Conveyor belt wear monitoring system | |
| DK3356391T3 (da) | Fremgangsmåde til oprensning af clostridial neurotoksin | |
| DK3307436T3 (da) | Mikrofluidanordning | |
| DK3259358T3 (da) | Forøget proteinekspression | |
| DK3296597T3 (da) | Krydshovedmotor | |
| EP3325857A4 (en) | scraper | |
| DK3292136T3 (da) | Penicillin-g-acylaser | |
| DK3271981T3 (da) | Tætning | |
| EP3384016A4 (en) | MANIPULATED PHAGEMIDES | |
| DE112015005905A5 (de) | Gurtschlossbringer | |
| EP3307242A4 (en) | PICn-01 |